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Introduction {#sec1}
============

Solid epithelial tumors are complex structures in which associated stromal cells, including fibroblasts, support cancer cells. During metastatic progression, cancer cells disseminate from their tissue of origin to re-establish the tumor structure in distant organs. Efficient metastasis requires the expression of specific molecules, such as POSTN and TNC, within the local microenvironment ([@bib16], [@bib23]). Therefore, a favorable microenvironment, or niche, is a crucial early requirement for metastatic progression ([@bib30]). However, the factors that promote efficient metastatic niche activation remain poorly characterized.

Cancer cells display heterogeneity in intrinsic tumorigenic potential; only a small subset of cells within tumors retains the ability of sustaining long-term growth ([@bib10], [@bib15]) as well as triggering relapses ([@bib5]). Cancer cells with the stem cell-like property of self-renewal can be defined functionally as cancer-initiating cells (CICs) for their capacity to elicit tumor growth. Moreover, metastatic initiating cells (MICs) can be distinguished from the bulk of cancer cells for their ability to establish metastasis. The functional assay for MICs involves determining the extent to which single cells can grow in a foreign tissue and is more challenging than the equivalent orthotopic transplantation assay used to assess the ability of CICs to initiate tumor growth. Although self-renewal ability is a common requirement for the re-initiation of a cancer cell mass at either primary or secondary sites, additional characteristics that discriminate MICs from CICs have not been explored. MICs have been identified previously in the mouse breast cancer model where mouse mammary tumor virus promoter controls the expression of the polyomavirus middle T antigen (MMTV-PyMT) ([@bib16]). We hypothesized that, in addition to intrinsic tumorigenic potential, MICs would exhibit a higher capacity for interacting with their niche by activating naive cells at distant sites ([@bib14]).

One strategy adopted by carcinoma cells to disseminate from the primary tumor mass is the activation of the developmental program epithelial-to-mesenchymal transition (EMT). During EMT, epithelial cells undergo a global change in cell architecture, leading to the loss of cell-cell adhesions in favor of cell-extracellular matrix (ECM) interactions and cell migration ([@bib31]). Notably, EMT modulations are not binary, but a graded range of intermediate states exists. The process is initiated by the activation of the EMT core transcription factors (TFs) Snail, Zeb, and Twist1 ([@bib26]), which drive epithelial cancer cells to switch off the expression of epithelial markers such as the adherens junction protein E-Cadherin and activate the expression of mesenchymal markers such as Vimentin. The tyrosine kinase AXL is a downstream effector of the EMT program ([@bib35]). EMT in breast cancer cells triggers an increase in AXL expression, and inhibition of AXL reduces the invasive and tumorigenic behavior of cancer cells ([@bib8], [@bib11], [@bib29], [@bib24]).

Interestingly, the induction of EMT TFs correlates with the emergence of stem cell-like properties ([@bib17], [@bib19]). This suggests that the gain of mesenchymal characteristics might not only affect dissemination from primary tumors but also boost the stem cell properties required for metastatic outgrowth. However, epithelial characteristics are re-acquired at metastatic locations via mesenchymal-to-epithelial transitions (METs), typically leading to the establishment of secondary tumors with epithelial phenotypes ([@bib33]). The outgrowth of metastases requires cancer cell self-renewal and growth ability. Therefore, in the context of metastatic growth, "stemness" is not strictly coupled to the mesenchymal features of cancer cells. The potential advantage of a more mesenchymal state of cancer cells at the metastatic site and the origin of their epithelial plasticity remain unclear.

In this study, we use breast cancer models to demonstrate that the EMT program is a key regulator of the enhanced niche activation capacity of MICs at secondary sites. We identify Thrombospondin 2 (THBS2) as a mesenchymal state-dependent effector of cancer cells that promotes stromal niche activation. Subsequently, the newly activated stroma promotes cancer cells to shift toward a more epithelial, BMP-dependent state compatible with proliferation. We elucidated a biphasic temporal regulation during metastatic colonization whereby the mesenchymal status of cancer cells promotes stromal activation, which, in turn, promotes cancer cell epithelial plasticity and their reversion to a more epithelium-like phenotype.

Results {#sec2}
=======

MICs Display Partial EMT Features {#sec2.1}
---------------------------------

In the mouse breast cancer MMTV-PyMT model, MICs were identified by co-expression of the CD24 and CD90 markers ([@bib16]). The gene expression profile of MICs (CD24^+^CD90^+^) was compared to that of non-MICs (CD24^+^CD90^−^) to generate a MIC signature ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We verified that high levels of Wnt signaling are a hallmark of metastatic cancer stem cells ([@bib15], [@bib16], [@bib20], [@bib28], [@bib34]), along with other characteristics associated with their high metastatic potential, such as active transforming growth factor β (TGF-β) signaling ([@bib25]) and Yap/Taz activity ([@bib6]). We also found that the MIC signature exhibited characteristic features of EMT and its related extracellular matrix remodeling ([Figure 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}B). In line with this, MICs freshly isolated from primary tumors displayed a mesenchymal phenotype with higher expression of Vimentin and the EMT-related receptor AXL as well as reduced E-cadherin levels ([Figures 1](#fig1){ref-type="fig"}B and 1C). This more mesenchymal phenotype was corroborated functionally using Matrigel collagen matrices where MICs, either in pure or mixed non-MIC/MIC spheroids, displayed enhanced single-cell invasive behavior compared with non-MICs ([Figures 1](#fig1){ref-type="fig"}D, 1E, and [S1](#mmc1){ref-type="supplementary-material"}C).

The capacity of MICs for invasion correlated with increased expression levels of actin cytoskeleton regulators and extracellular matrix components ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). EMT in MICs was further confirmed by the higher expression and nuclear localization of EMT TFs ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). However, the high level of heterogeneity within the MIC population suggests a graded EMT with intermediate "partial EMT" states rather than a simple binary transition. The MIC expression signature also correlated with different secretome gene sets ([Figure 1](#fig1){ref-type="fig"}A). Some of these secreted factors have been reported previously to play a role in metastasis, such as TNC, SPARC, or CCL2 ([@bib23], [@bib32], [@bib27]).

We went on to investigate the influence that the observed partial EMT status of MICs has on their capacity for metastatic initiation following dissemination. Because the metastatic behavior of MMTV-PyMT MICs might be regulated by the activity of other pathways, such as WNT ([Figure 1](#fig1){ref-type="fig"}A), we selected a broader mesenchymal cancer cell pool expressing AXL, including the MIC (CD24^+^CD90^+^) population ([Figure S2](#mmc1){ref-type="supplementary-material"}A). As expected, the CD24^+^AXL^+^ population isolated from primary tumors displayed partial mesenchymal features ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). We next tested CD24^+^AXL^+^ cells for their cancer initiation and metastatic initiation potential using orthotopic transplantation and tail vein injection, respectively ([Figures 1](#fig1){ref-type="fig"}F and 1G). Both assays require cancer cell stemness to reinitiate and sustain a cancer cell mass, either in a collective challenge within their organ of origin with favorable niches or when seeded via circulation as single cells in a likely less favorable "foreign" organ. We observed no difference in primary tumor growth for CD24^+^AXL^+^ and CD24^+^AXL^−^ cells, indicating that the subpools exhibit a comparable capacity for cancer initiation ([Figure 1](#fig1){ref-type="fig"}H). Indeed, for MMTV-PyMT tumor cells, more mesenchymal characteristics do not appear to influence tumor initiation ability. The more epithelial CD24^+^SCA1^+^ subpool ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F) identified previously for their tumor initiation capacity ([@bib13]) displayed a similar tumor initiation potential as the more mesenchymal CD24^+^AXL^+^ or MIC pools ([Figures S2](#mmc1){ref-type="supplementary-material"}G--S2I). Strikingly, CD24^+^AXL^+^ cancer cells show a higher lung metastasis competence compared with their more epithelial counterparts ([Figure 1](#fig1){ref-type="fig"}I). This suggests that the common mesenchymal characteristics observed within the CD24^+^AXL^+^ and MIC CD24^+^CD90^+^ cancer cells might be linked functionally to their metastatic competence, independent of an advantage in intrinsic stemness potential displayed in a favorable microenvironment.

MICs Promote Quicker Lung Fibroblast Activation {#sec2.2}
-----------------------------------------------

The highly secretory mesenchymal status of MICs might provide an increased capacity of generating a favorable environment, or niche, in distant sites ([Figure 1](#fig1){ref-type="fig"}A). We examined this suggestion by analyzing the activation of lung stromata around disseminated AXL^+^ or AXL^−^ cancer cell early after their extravasation into the lungs. In line with our hypothesis, CD24^+^AXL^+^ cells are surrounded by higher numbers of smooth muscle actin (SMA)-activated fibroblastic stroma compared with CD24^+^AXL^−^ cells. We observed no difference in their tissue localization, in particular in their proximity to lung endothelial cells ([Figures 2](#fig2){ref-type="fig"}A--2D). To test whether niche activation ability is a common advantage conferred by the mesenchymal status of CD24^+^AXL^+^ and MIC pools, we measured the ability of isolated MICs to trigger features of cancer-associated fibroblasts (CAFs) in normal lung fibroblasts ex vivo. Sorted MICs or non-MICs with a GFP-labeled normal lung fibroblast cell line (NLF3) were plated and monitored for the induction of early fibroblast activation markers ([Figure 2](#fig2){ref-type="fig"}E). Because all cancer cells are capable of fibroblast activation to some extent, we used low cell numbers to increase the assay's sensitivity. After 24 hr, fibroblasts co-cultured with MICs exhibited early nuclear YAP translocation, required for CAF induction, and higher fibroblast activation protein (FAP) expression compared with fibroblasts cultured with non-MICs ([Figures 2](#fig2){ref-type="fig"}F--2H; [@bib4]). To verify that the induction of these markers represents fibroblast activation, we performed functional gel contraction assays to examine the ability of fibroblasts to physically remodel the ECM. Limited numbers of cell-sorted MICs or non-MICs from primary tumors were seeded in the upper chamber of a trans-well dish. In the lower chamber of the co-culture, normal lung fibroblasts (NFs) freshly isolated from wild-type mouse lungs were embedded in collagen-Matrigel matrices ([Figure 2](#fig2){ref-type="fig"}I). Importantly, we observed that MICs trigger significantly greater fibroblast-driven gel contraction compared with the other primary cancer cells ([Figures 2](#fig2){ref-type="fig"}J). In parallel, a gain of a CAF gene expression signature was induced in fibroblast co-cultured with MICs. Collectively, these data provide direct evidence that cancer cells displaying partial EMT characteristics show an enhanced ability to generate activated fibroblasts, a crucial component of the metastatic niche.

Thrombospondin 2 Secretion Increases Stromal Activation Capacity and Confers a Metastatic Advantage in MICs {#sec2.3}
-----------------------------------------------------------------------------------------------------------

To understand the mechanism underlying the enhanced capacity for fibroblast activation, we tested several MIC-specific secreted proteins for their ability to activate fibroblasts ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). We found that purified recombinant THBS2 significantly enhanced the gel contraction capacity of fibroblasts ([Figure 3](#fig3){ref-type="fig"}A). We observed that exposure of lung fibroblasts to purified THBS2 led to activation of integrin β1 and the phosphorylation of its downstream effector focal adhesion kinase (pFAK) ([Figures 3](#fig3){ref-type="fig"}B and 3C). Importantly, a specific integrin β1-blocking antibody (β1BA) arrested the THBS2-dependent integrin cascade as well as fibroblast activation ([Figures 3](#fig3){ref-type="fig"}B--3D). To examine the role THBS2 might play in tumorigenicity, we used a specific short hairpin RNA (shRNA) targeting *Thbs2* mRNA (shTHBS2) to knock down its expression in primary MMTV-PyMT cancer cells (PyMT) ([Figure 3](#fig3){ref-type="fig"}E). Importantly, THBS2 depletion rendered cancer cells less able to activate lung fibroblasts ([Figure 3](#fig3){ref-type="fig"}F). Furthermore, shTHBS2 cancer cells were reduced dramatically in their capacity for lung metastatic colonization upon intravenous injection ([Figure 3](#fig3){ref-type="fig"}H). However, this is unlikely to be due to an effect on intrinsic cancer cell stemness because shTHSB2 PyMT cells maintained their ability to initiate early primary tumor growth in vivo or form spheres in vitro ([Figure 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}C). Similar findings were obtained using a second shRNA to block THBS2 secretion ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3H). Because THBS2 is highly expressed in only a subset of PyMT cells, we tested the consequence of exogenous *Thbs2* gene expression in all PyMT cells. Importantly, broad THBS2 secretion resulted in increased early metastatic growth in the lungs upon direct seeding ([Figure 3](#fig3){ref-type="fig"}I). These data support the clinical correlation of high *Thbs2* expression with poor prognosis in advanced-stage human breast cancers ([Figure S3](#mmc1){ref-type="supplementary-material"}I). Together, these results suggest that MICs mediate efficient fibroblast activation through THBS2 secretion and that this is critical for efficient metastatic initiation within the secondary tissue.

The Niche Activation Capacity of Metastatic Cancer Cells Depends on Their Partial Mesenchymal Status {#sec2.4}
----------------------------------------------------------------------------------------------------

The previous results reveal high niche activation ability as a crucial characteristic of MICs. Interestingly, we also found that their partial EMT phenotype defined by AXL expression was sufficient to determine their metastatic competence ([Figure 1](#fig1){ref-type="fig"}I). Therefore, we investigated whether the high niche activation ability of MICs is linked functionally to their AXL mesenchymal status. We used two approaches to downregulate AXL. First we used the AXL-specific small molecule inhibitor R428 ([@bib11]), and second we used an shRNA to target *Axl* mRNA ([@bib8]). Brief exposure of MICs to R428 triggered an overall shift toward a more epithelial phenotype with lower Vimentin and AXL expression and higher E-cadherin levels ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}A). Accordingly, we detected a reduction in the expression of EMT-TFs and motility in MICs ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Similar phenotypic changes occurred in the basal human breast cancer cell line MDA-MB-231 (MDA231) following treatment with R428. Indeed, although MDA231 cells, which homogeneously express AXL, typically display mesenchyme-like features, a single pulse of R428 reduced the expression of AXL and Vimentin and cell motility for up to 48 hr ([Figures S4](#mmc1){ref-type="supplementary-material"}D--S4G). Interestingly, upon R428-mediated mesenchymal inhibition, cancer cells also reduced the expression of secreted factors, including THBS2 ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}H). Concomitantly, the fibroblast activation ability of R428-treated metastatic cells was impaired dramatically ([Figure 4](#fig4){ref-type="fig"}D). Because similar results were found using an shRNA against *Axl* mRNA in primary PyMT cells ([Figure S5](#mmc1){ref-type="supplementary-material"}A), we can exclude non-specific effects of the small molecule inhibitor R428. Indeed, shRNA-induced AXL downregulation in PyMT cells reduced THBS2 secretion and ex vivo fibroblast activation abilities ([Figures 4](#fig4){ref-type="fig"}E and 4F). Notably, the expression of *Thbs2* appears to be highly linked to the expression of the *Axl* and *Twist1* genes in human tumor biopsies ([Figure S4](#mmc1){ref-type="supplementary-material"}I). These data demonstrate that the mesenchymal status of MICs is directly related to their enhanced capacity for fibroblast activation.

Cancer Cells Require AXL Mesenchymal Features to Facilitate Fibroblast Activation {#sec2.5}
---------------------------------------------------------------------------------

We showed that MICs isolated from primary tumors are in an AXL-positive mesenchymal state. Therefore, we went on to examine the mesenchymal status of cancer cells at the target site by monitoring AXL expression during early colonization. We detected two distinct phases of AXL expression: a first phase, where the PyMT EMT MIC subpool maintains AXL, and a second phase, where the AXL-positive phenotype is lost coincidentally with MIC expansion in the lungs ([Figure 5](#fig5){ref-type="fig"}A). Similar biphasic AXL expression was observed in the MDA231 cell line ([Figure 5](#fig5){ref-type="fig"}B). Because the ability of cancer cells to trigger the niche is crucial for metastatic establishment ([Figure 3](#fig3){ref-type="fig"}) and dependent on the mesenchymal phenotype ([Figure 4](#fig4){ref-type="fig"}), we assessed whether the maintenance of AXL is required for the first phase of metastatic colonization. To do this, we inhibited AXL activity only during the first colonization phase by pre-treating cancer cells with the R428 inhibitor prior to intravenous injection and continued treatment in vivo for 7 days ([Figure 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}B). Notably, although R428 pre-treatment did not alter cancer cell extravasation ([Figure S5](#mmc1){ref-type="supplementary-material"}C), it did significantly reduce metastasis after 5 weeks ([Figures 5](#fig5){ref-type="fig"}D--5F). Remarkably, only R428 pre-treatment 24 hr before seeding into the lung was sufficient to inhibit metastatic establishment ([Figure 5](#fig5){ref-type="fig"}E), suggesting that AXL mesenchymal features are required early after metastatic cell arrival to new tissue. Although short-term inhibition of AXL decreased metastatic competence, this had no effect on proliferation, self-renewal, and 3D cancer cell mass growth in vitro ([Figures S5](#mmc1){ref-type="supplementary-material"}D--5G), or primary tumor initiation in vivo ([Figure S5](#mmc1){ref-type="supplementary-material"}H). Interestingly, enhancing THBS2 expression in the MDA-MB-231 cell line partially rescued metastasis upon AXL inhibition in spite of the fact that THBS2 overexpression only provided a positive trend toward metastasis in these cells ([Figures 5](#fig5){ref-type="fig"}G, [S5](#mmc1){ref-type="supplementary-material"}I, and S5J). This result is in line with the observation that AXL-mesenchymal cells show a THBS2-mediated advantage in niche activation. We also observed a block in metastasis upon AXL inhibition using shRNA knockdown in PyMT cells ([Figures 5](#fig5){ref-type="fig"}H and 5I). Furthermore, treatment of a second mouse breast cancer cell line (4T1) with shTHBS2 or shAXL also reduced the metastatic ability of 4T1 cells ([Figures S5](#mmc1){ref-type="supplementary-material"}K and S5L). Together, these results suggest that the first phase of metastatic colonization requires the niche activation capacity provided by the AXL mesenchymal characteristics.

Activated Stroma Modulates the EMT of Cancer Cells toward a More Epithelial State {#sec2.6}
---------------------------------------------------------------------------------

The previous results highlight the requirement of a mesenchymal state for metastatic initiation upon seeding at the target site. However, when cancer cells start growing within the metastatic tissue, AXL expression is downregulated ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [6](#fig6){ref-type="fig"}A). ImageStream analysis showed that, coincident with AXL downregulation, GFP^+^ cancer cells growing in the lungs exhibit reduced expression of the EMT transcription factor Twist1 ([Figures 6](#fig6){ref-type="fig"}B, 6C, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B). This suggests that the previously reported EMT inhibition at the secondary site ([@bib33]) is controlled temporally within the second phase of metastatic colonization. Therefore, we investigated the changes that occur in metastatic cells during this time period.

Ex vivo co-culture (as shown in [Figure 2](#fig2){ref-type="fig"}E) demonstrated that, concomitant with fibroblast activation ([Figures 2](#fig2){ref-type="fig"}F--2H), MICs express lower levels of *Axl*, *Twist1* ([Figures 6](#fig6){ref-type="fig"}D and 6E), and overall EMT TF mRNA ([Figure S6](#mmc1){ref-type="supplementary-material"}C). To track the phenotypic changes during this time, cancer cells were co-cultured with CAFs for 24 hr under adherence conditions ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Here we found that MICs reduced expression of Vimentin and AXL and increased expression of E-cadherin ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). These results suggest that crosstalk between fibroblasts and cancer cells triggers alterations in both compartments; namely, activation of fibroblasts and consequent reacquisition of epithelial characteristics by cancer cells. To functionally validate these changes in the MIC EMT state, we analyzed their 3D invasion modality as they first come in contact with CAFs. In line with previous studies ([@bib7], [@bib37]), carcinoma cells in a non-invasive epithelial state (non-MICs) activated both single and collective cell invasion modalities. Strikingly, in line with the downregulation of mesenchymal markers, MICs displayed a notable reduction in single-cell migration when surrounded by CAFs ([Figures 6](#fig6){ref-type="fig"}F and 6G).

We next investigated the potential molecular mechanism of CAF-driven changes in cancer cells. TGF-β signaling has been implicated extensively in metastasis ([@bib25]). High TGF-β signaling favors early metastatic colonization, whereas its subsequent reduction is important for metastatic outgrowth ([@bib38]). Because TGF-β signaling, which is active in MICs ([Figure 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}B), could be linked functionally to their mesenchymal status ([@bib6]), we assessed whether modulation of TGF-β signaling in MICs associates with the reacquisition of more epithelial characteristics. Using ImageStream analysis, we monitored the dynamics of activation of the TGF-β effector SMAD2-3 in metastasizing cells in vivo. As AXL^+^ mesenchymal cells in the lung transit from the first to the second phase of colonization, the number and staining intensity of pSMAD2-3^+^ cells decreased similarly to Twist1 expression ([Figure 6](#fig6){ref-type="fig"}H, [S6](#mmc1){ref-type="supplementary-material"}G, and S6I). These data are in agreement with the previous evidence showing that a reduction in TGF-β signaling is required for the acquisition of the proliferative status necessary for metastatic outgrowth ([@bib18]). Conversely, the activation levels of BMP-dependent pSMAD1-5 was maintained during the second phase of colonization, and the number of pSMAD1-5^+^ cells increased ([Figures 6](#fig6){ref-type="fig"}I, [S6](#mmc1){ref-type="supplementary-material"}H, and S6J). In line with this, we observed that the levels of inhibitor of differentiation 1 (ID1), a BMP/pSMAD1-5 target gene needed for cell proliferation during metastatic outgrowth ([@bib9]), were maintained, in particular in Twist1^−^ cells ([Figures 6](#fig6){ref-type="fig"}J and 6K). Notably, this modulation of ID1 in cancer cells could be recapitulated in vitro by exposure to CAF-conditioned medium (CaCM), which increases the levels of ID1 in a BMP-dependent manner ([Figures 6](#fig6){ref-type="fig"}L and 6M). Importantly, treatment with the specific inhibitor LDN193189 in vivo resulted in reduced metastatic capacity ([Figures 6](#fig6){ref-type="fig"}N and 6O), suggesting that BMP/pSMAD1-5 activity does indeed play a significant role in the second phase of colonization.

Together, these data show that, in the second colonization phase, the phenotypic changes observed in metastasizing cancer cells toward a more epithelial state correlate with an inhibition of TGF-β signaling and the enhanced BMP signaling necessary for metastatic outgrowth.

The Second Metastatic Colonization Phase Requires Temporal Regulation for Efficient Metastatic Establishment {#sec2.7}
------------------------------------------------------------------------------------------------------------

We showed that the mesenchymal status of cancer cells during the first phase of colonization is required for metastatic establishment. However, when CD24^+^AXL^+^ mesenchymal cancer cells accumulate in the lung, they revert to an AXL-negative, more epithelial state ([Figure 5](#fig5){ref-type="fig"}) following interaction with newly activated fibroblasts ([Figure 6](#fig6){ref-type="fig"}). If these two events were linked causally, then it would be expected that a temporal regulation of epithelial plasticity is critical for metastatic outgrowth. Initially, to probe this hypothesis, we induced an early mesenchymal reversion of metastatic cells by R428 treatment during the second phase of colonization ([Figure 7](#fig7){ref-type="fig"}A). This AXL inhibition no longer blocks the metastatic establishment of MDA231 cells ([Figure S7](#mmc1){ref-type="supplementary-material"}A) and increases metastasis of primary PyMT cells ([Figures 7](#fig7){ref-type="fig"}B and 7C), suggesting that inhibiting EMT in this phase promotes metastasis. We observed that AXL inhibition in late-stage metastases did not alter the number of metastatic nodules ([Figures 7](#fig7){ref-type="fig"}A and 7B). Next, we delayed mesenchymal reversion in vivo by exogenous expression of the *Axl* gene (LTR-AXL) in cancer cells ([Figure 7](#fig7){ref-type="fig"}D). This leads to an exacerbated AXL-positive mesenchymal phenotype ([Figures 7](#fig7){ref-type="fig"}G, 7J, and [S7](#mmc1){ref-type="supplementary-material"}B) without altering the proliferation capacity ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Importantly, preventing early AXL downregulation in metastasizing LTR-AXL-expressing cells delayed initial growth in the lungs ([Figures 7](#fig7){ref-type="fig"}E and 7F) and, ultimately, led to a reduction in the metastatic potential of both PyMT and MDA231 cancer cells ([Figures 7](#fig7){ref-type="fig"}H, 7I, and 7K). These data support the idea that downregulation of AXL is required during the second colonization phase to allow the transition to a more epithelial proliferative state. Interestingly, the overexpression of AXL in cancer cells led to a reduction in metastatic capacity specifically because an enhancement of primary tumor growth was detected ([Figure S7](#mmc1){ref-type="supplementary-material"}D). This is likely due to an increase in AXL tyrosine kinase receptor activity at the early stages of tumor initiation, leading to the generation of larger tumors without obvious histologic changes after tumor establishment ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7F).

Discussion {#sec3}
==========

Successful establishment of metastases requires cancer cells with self-renewal properties to disseminate from their tissue of origin and re-initiate growth at secondary sites. The evidence that experimental induction of EMT in epithelial cells triggers stem cell characteristics suggests a unified mechanism for cancer metastasis. However, the plasticity of the EMT program from dissemination to distant colonization during the metastatic process makes the direct relationship between EMT and stemness controversial ([@bib33], [@bib17], [@bib19], [@bib36], [@bib3], [@bib21]) and suggests that metastatic cancer cells are likely to undergo a partial EMT that can be modulated toward a more mesenchymal or epithelial state ([@bib22]). Furthermore, although the requirement of an EMT inhibition at the metastatic site has been reported previously ([@bib33]), the dynamic regulation of the mesenchymal/epithelial transition is currently unknown. Using breast cancer models, we highlight the importance of the more mesenchymal phenotype of MICs during the early phase of metastatic colonization. Moreover, we demonstrate the requirement for AXL mesenchymal state-dependent THBS2 secretion in mediating enhanced niche activation. We also identify a subsequent phase of colonization where the mesenchymal phenotype of cancer cells is downmodulated by the interaction with the newly induced niche. This crosstalk leads to inhibition of TGF-β signaling and pSMAD1-5-dependent outgrowth, shifting cancer cells toward a more epithelial and proliferative state. Blocking the effectors of these pathways during this biphasic process reduces metastasis: THBS2 expression during the first phase or pSMAD1-5 activity during the second phase. Here we identify epithelial plasticity as a crucial determinant of metastatic colonization and describe how disruption of AXL-dependent phenotypic modulation is sufficient to reduce metastatic efficiency.

In agreement with the previously observed link between the EMT program and the gain in stemness ([@bib17], [@bib19]), we found that the MICs of the MMTV-PyMT tumor model ([@bib16]) display a mesenchymal phenotype ([Figure 1](#fig1){ref-type="fig"}A--1D and [S1](#mmc1){ref-type="supplementary-material"}). However, using the EMT downstream effector AXL as a marker for mesenchymal cancer cells, we demonstrate that, within the MMTV-PyMT hierarchy, the mesenchymal features per se do not confer a differential tumor initiation ability ([Figure 1](#fig1){ref-type="fig"}H and [S2](#mmc1){ref-type="supplementary-material"}). Nonetheless, a more mesenchymal state promotes growth at a less favorable distant environment ([Figure 1](#fig1){ref-type="fig"}I). This correlates with a higher capacity of CD24^+^AXL^+^ cells to induce stromal activation early after infiltration of the secondary tissue ([Figures 2](#fig2){ref-type="fig"}A--2D). Our work suggests that the increased intrinsic ability to trigger a favorable microenvironment at the naive target site provides a metastatic initiation advantage. Indeed, both the MIC subpool of MMTV-PyMT cancer cells as well as the metastatic human MDA-MB-231 cell line show higher niche component activation ability according to their mesenchymal phenotype ([Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}) and THBS2 secretion ([Figure 3](#fig3){ref-type="fig"}). We show here that THBS2 is capable of triggering fibroblast activation via integrin signaling and enhancing early metastatic colonization ([Figure 3](#fig3){ref-type="fig"}I). This finding is supported by computational analyses defining *Thbs2* as one of the three genes associated with a stromal desmoplastic reaction and high metastatic risk ([@bib12]) as well as by the clinical evidence of its correlation with poor prognosis in high-grade human breast cancers ([Figure S3](#mmc1){ref-type="supplementary-material"}I). However, in rare circulating cancer cell clusters that exhibit high metastatic potential, the mechanism we describe may be circumvented ([@bib1]). In this context, the cells within the cluster may create their own favorable niche and, therefore, bypass the requirement for a mesenchymal state and associated niche activation.

Our results support the concept that stemness is unperturbed by the mesenchymal/epithelial plasticity of metastatic cells and correlate with a flexible partial EMT state rather than with a stable binary EMT program. We confirmed that, to efficiently generate a cancer cell mass at a distant site, cells regain a more epithelial phenotype ([@bib33]). Notably, we now show that this modulation is controlled temporally during the second phase of metastatic colonization ([Figure 7](#fig7){ref-type="fig"}). Indeed, prolonged *Axl* gene activation in cancer cells strongly reduces metastatic ability ([Figures 7](#fig7){ref-type="fig"}H and 7K). AXL expression in the context of breast cancer lung metastasis opposes primary tumor initiation ([Figures 7](#fig7){ref-type="fig"}G--7K and [S7](#mmc1){ref-type="supplementary-material"}D), likely because of differences in the requirement of its tyrosine kinase receptor function, which is also crucial for other cancer types ([@bib2]).

Remarkably, we provide experimental evidence that epithelial plasticity is mediated by crosstalk between the cancer cell and stroma ([Figure 6](#fig6){ref-type="fig"}). During the second colonization phase, the newly activated fibroblasts generated during the first phase induce a phenotype switch in MICs. BMP-dependent ID1 activation in cancer cells is triggered by exposure to CaCM ([Figures 6](#fig6){ref-type="fig"}L and 6M). This effect, observed in vitro, is corroborated in vivo by the enhancement of pSMAD1-5 activity and downmodulation of TGF-β signaling in favor of an ID1-positive proliferative state. Indeed, treatment of mice with the specific BMP inhibitor LDN193189 during the second colonization phase inhibits metastasis ([Figures 6](#fig6){ref-type="fig"}N and 6O).

Overall, this study provides a refined definition of distant colonization by more mesenchymal cancer cells where their niche-activation capacity is linked to their mesenchymal status and THBS2 secretion. Subsequently, activated fibroblasts drive MICs to revert to a more epithelial phenotype. This model highlights the importance of cancer cell-stroma crosstalk in modulating the optimal phenotype for cancer cells during the dynamic metastatic process.

Experimental Procedures {#sec4}
=======================

Statistical Analysis {#sec4.1}
--------------------

Statistical analyses were performed using Prism software (GraphPad Software). p values were obtained from two-tailed Student's t tests with paired or unpaired adjustment. One-column t test was used for comparisons with a normalized value. One-tailed t test was used for [Figure 4](#fig4){ref-type="fig"}E. Where indicated, two-way ANOVA was used to perform multiple comparisons or multiple variables analysis between experimental groups. Significance was set at p \< 0.05. Graphs show the symbols describing the p value (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001).

Animal Procedures {#sec4.2}
-----------------

All experimental procedures involving mice were performed in accordance with United Kingdom regulations under project license PPL 80/2531. Further information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ImageStream Analysis {#sec4.3}
--------------------

Lungs or Matrigel collagen gels from co-culture experiments were digested and dissociated to obtain a single-cell suspension, stained with a live/dead fixable dye, fixed, and stained with the indicated primary antibodies (antibody descriptions and working dilutions can be found in [Table S4](#mmc1){ref-type="supplementary-material"} and in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Tumor cells in the lung were identified by GFP expression. The acquired ImageStream data were analyzed using Amnis IDEA management software.
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![The Mesenchymal Features of MICs Are Part of Their Metastasis-Initiating Potential\
(A) Circos plot displaying selected gene signatures correlating positively with MIC-upregulated genes (see also [Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Black blocks highlight metastasis-promoting genes either known (white) or described in this study (red).\
(B and C) Representative immunofluorescence images (B) of non-MICs (CD24^+^CD90^−^) and MICs (CD24^+^CD90^+^) stained with E-cadherin, Vimentin, and AXL antibodies. Scale bar, 40 μm. Staining quantification is shown in (C). Data are from one representative experiment of five.\
(D) Spheroid invasion assay. Shown are representative fluorescence images of MIC or non-MIC spheroids from actin-GFP/PyMT tumors in Matrigel:collagen I. Scale bar, 100 μm.\
(E) Mixed spheroid invasion assay. The histogram shows the number of cells invading as single cell (1:9 actin/GFP MICs:non-labeled non-MICs) in Matrigel:collagen I (see also [Figure S1](#mmc1){ref-type="supplementary-material"}C).\
(F and G) Schematic showing a collective cell challenge for primary tumor growth into mammary fat pads (F) or a single-cell challenge for lung metastasis via the tail vein (G).\
(H) Box plot showing the primary tumor burden in grams generated by the indicated sorted cells after overnight culture. Shown are data from three experiments using the indicated cell numbers (n = 4/group). IV, intravenous.\
(I) Box plot showing the lung metastatic burden 5 weeks after tail vein injection. Two independent experiments are shown (n = 5--6/group). Shown are representative images of lungs with GFP^+^ metastases.\
Error bars represent SD in (C) and SEM in all other plots. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001; ns, not significant.](gr1){#fig1}

![MICs Have a Higher Capacity to Activate Fibroblasts\
(A--D) Representative pictures showing single GFP^+^ cells (green) from the indicated subpools 72 hr after intravenous injection into RAG1-deficient mice. (A) DAPI staining (blue) and SMA (red); quantified in (C). (B) DAPI staining (blue) and Endomucin (red); quantified in (D). Scale bars, 10 μm. n = 32--50 cells.\
(E) Schematic of the cancer cell and GFP^+^ normal lung fibroblast cell line (NLF3) co-culture setting.\
(F and G) Representative images of (F) early YAP nuclear translocation in NLF3 or (G) FAP levels in NLF3 cells 24 hr after plating. Scale bars, 40 μm (F), 70 μm (G).\
(H) Chart indicating the levels of FAP in NLF3 cells from (G). Data are from one representative experiment of three.\
(I) Schematic displaying the cancer cell and NLF3 co-culture setting.\
(J) Representative images of the gel contraction by NLF3 assayed as in (I). The histogram shows the gel area of three independent experiments (n = 8/group).\
(K) Quantitative real-time PCR analysis of the levels of CAF-defining genes in primary NF after co-culture with MICs (NF-MIC) or nonMICs (NF-nonMIC). Data are from at least three experiments in triplicate normalized to *Gapdh*. p = 0.0235 by ANOVA comparing differences between the NF, NF-non-MIC, and NF-MIC gene signatures.\
Error bars represent SD in (H) and SEM in all other plots. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. ns, non-significant.](gr2){#fig2}

![Cancer Cell-Derived THBS2 Enhances Fibroblast Activation\
(A) Gel contraction induced by NLF3 after 3 days of exposure to recombinant CCL7 or THBS2. Top: representative NLF3-gels. Bottom: gel area quantification of three independent experiments (n = 12/group).\
(B and C) Levels of the active isoform of integrin β1 (clone 9EG7) and its downstream effector FAK (total or phosphorylated) in NLF3 for the indicated groups. Data are from one representative experiment of two. Quantification is shown in (B) and representative images in (C). Scale bars, 20 μm.\
(D) Gel contraction induced by NLF3 after co-culture with recombinant THBS2 with or without integrin β1-blocking antibody. Top: representative NLF3-gels. Bottom: gel area quantification of two independent experiments (n = 4--16/group).\
(E) Quantitative real-time PCR analysis of the mRNA expression level of *Thbs2* by the indicated cells. Data are from three different experiments in triplicate normalized to Gapdh.\
(F) Gel contraction induced by NLF3 after co-culture with the indicated cancer cells. Top: representative NLF3-gels. Bottom: gel area quantification of two independent experiments (n = 10--12/group).\
(G) Box plot showing early primary tumor growth of primary PyMT cells expressing shCONTROL or shTHBS2 constructs in an orthotopic challenge (n = 6/group).\
(H) Box plot showing the metastatic burden from PyMT cells expressing shCONTROL or shTHBS2 constructs 5 weeks after tail vein injection (n = 7--11/group). The superficial lung metastasis number was evaluated.\
(I) Box plot displaying the metastatic cell content by flow cytometry 20 days after tail vein injection of PyMT control or THBS2ORF-expressing cells (n = 8/group).\
Error bars represent SD in (B) and SEM in all other plots. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.](gr3){#fig3}

![The Mesenchymal Status of Cancer Cells Drives Fibroblast Activation\
(A) Representative images showing the expression of E-cadherin, Vimentin, and AXL in MICs 24 hr after treatment with DMSO or R428. Scale bar, 20 μm. See also [Figure S4](#mmc1){ref-type="supplementary-material"}A.\
(B) *Axl* gene expression levels in PyMT cells pre-treated with or without R428 as determined by quantitative real-time PCR analysis. Data are from three different experiments in triplicate (normalized to *Gapdh*).\
(C) THBS2 secretion in the media collected from the indicated cancer cells 24 hr after R428 pre-treatment as measured by ELISA. Left: PyMT subpools, non-MIC data from three experiments in duplicate; MIC ± R428 treatment, data from seven experiments in duplicate. Right: MDA-MB-231 cell line (MDA231), data from four experiments in duplicate.\
(D) Gel contraction induced by NLF3 after exposure to MDA231 pre-treated with DMSO or R428. Top: representative NLF3 gels. Bottom: gel area quantification of three independent experiments (n = 12/group).\
(E) THBS2 secretion in the media collected from the indicated cancer cells 24 hr after plating by ELISA. Data are from three different experiments in duplicate.\
(F) Gel contraction induced by NLF3 after exposure to the indicated cells. Top: representative NLF3 gels. Bottom: gel area quantification of two independent experiments (n = 7--9/group).\
Error bars represent SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. ns, non-significant.](gr4){#fig4}

![The Mesenchymal Status Is Regulated Temporally during Metastatic Colonization\
(A) Flow cytometry analysis of the percentage of AXL^+^ MICs (red, left y axis) and total MICs (black, right y axis) among total GFP^+^ cancer cells in the lung 4 and 12 days after tail vein injection (n = 8--9/group from two independent experiments).\
(B) Flow cytometry analysis of the percentage of AXL^+^GFP^+^ MDA-MB-231 cells (MDA231) among total GFP^+^ cancer cells in the lung 4 and 12 days after tail vein injection (n = 3/group).\
(C) Schematic of the R428 treatment setting for PyMT or MDA231 cells. IV, intravenous.\
(D) Box plot showing the metastatic burden of MDA231 cells exposed to DMSO (n = 13) or R428 (n = 8) during the first week of colonization. The superficial lung metastasis number was evaluated. Shown are representative pictures of metastatic lungs. Scale bar, 300 μm.\
(E) Box plot displaying the metastatic burden of PyMT cells pre-treated with DMSO (n = 14) or R428 (n = 5). In the last group (light blue, n = 9) mice were additionally treated with R428 during the first week of colonization. The superficial lung metastasis number was evaluated.\
(F) Representative H&E staining of metastatic lung sections from the indicated mice. Scale bar, 100 μm.\
(G) Box plot showing the metastatic burden of control (Venus) or THBS2-expressing MDA231 cells treated as in (C) (n = 7--5/group). Micrometastases were evaluated in histological sections of one lung lobe (see also [Figure S5](#mmc1){ref-type="supplementary-material"}J).\
(H) Box plot displaying early primary tumor growth after orthotopic transplantation of the indicated primary PyMT cells (n = 6/group).\
(I) Box plot showing the metastatic burden of the indicated PyMT cells after tail vein injection (n = 5--8/group). The superficial lung metastasis number was evaluated.\
Error bars represent SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. ns, non-significant.](gr5){#fig5}

![Attenuation of the Metastatic Cell Mesenchymal Phenotype\
(A) Flow cytometry analysis changes in AXL expression in AXL^+^ cancer cells seeded in the lungs after the indicated times points (n = 8--9/group). Data are from one representative experiment of two.\
(B and C) ImageStream analysis changes in Twist1 expression in AXL^+^ cancer cells seeded in the lungs after the indicated times points (n = 4--5/group). (B) Quantification of Twist1^+^ cells from one representative experiment of three. (C) Contour plot of representative lungs from (B) showing Twist1 staining intensity.\
(D and E) MIC changes after 3--5 days of co-culture with NLF3 as in [Figure 2](#fig2){ref-type="fig"}E. (D) Flow cytometry quantification of AXL expression levels. Data are from one representative experiment (n = 4/group) of two. (E) ImageStream analysis of the percentage of Twist1^+^ cells. Data are from one representative experiment (n = 4/group) of two.\
(F and G) Spheroid invasion assay. Labeled MIC or non-MIC (green) spheroids were imaged 48 hr after seeding into Matrigel:collagen I with or without CAFs. (F) Quantification of single (left) and collective (right) cell invasion. Data are from one representative experiment of two. (G) Representative spheroid images. Arrows indicate single invading cells. Scale bar, 100 μm.\
(H--K) ImageStream analysis of pSMAD2-3^+^ (H), pSMAD1-5^+^ (I), ID1^+^ (J), and ID1^+^Twist1^−^ (K) cell percentages in the lung 2 or 12 days post-seeding (n = 3--5/group).\
(L and M) Expression levels of ID1 in primary CD24^+^AXL^+^ tumor cells 24 hr after exposure to the indicated media and in the presence of LDN193189 inhibitor determined by (L) western blot using Actin as a loading control (one representative experiment of two) or (M) immunofluorescence staining quantification (one representative experiment of two).\
(N) Schematic showing the in vivo LDN193189 treatment setting.\
(O) Box plot displaying the metastatic burden of PyMT cells in mice treated with vehicle or LDN193189. Shown are representative H&E-stained lung sections (n = 9--12/group). Scale bar, 100 μm.\
Error bars represent SD in (M) and SEM in all other plots. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p\<0.001, ^∗∗∗∗^p \< 0.0001. ns, non-significant.](gr6){#fig6}

![EMT-Stabilized Cells Do Not Metastasize Efficiently\
(A) Schematic showing the R428 treatment setting.\
(B) Box plot displaying the metastatic burden of mice injected with primary PyMT cells for the indicated groups: DMSO, n = 11; R428, days 10--15, n = 10; and R428, days 25--35, n = 7. The superficial lung metastasis number was evaluated.\
(C) Representative images of the indicated lung sections. Scale bar, 100 μm.\
(D) Schematic of the LTR-driven lentiviral plasmid expressing the human *Axl* open reading frame (ORF) (top) and control plasmid (bottom).\
(E and F) Flow cytometry analysis showing the percentage of total cancer cells (black) and AXL^+^ cells (blue) in the lung 3 or 4 days after intravenous injection of MDA231 expressing the control-GFP construct (E) or LTR-AXL construct (F). Data are displayed as the group average relative to day 3 (n = 4--6/group).\
(G) Representative flow cytometry plot showing the expression levels of AXL in the indicated primary PyMT cells.\
(H) Box plot showing superficial lung metastasis quantification after intravenous injection of PyMT cells expressing control-GFP or LTR-AXL constructs (n = 10/group).\
(I) Representative H&E staining of lung sections of mice injected with MDA231 of the indicated groups. Scale bar, 100 μm.\
(J) Representative flow cytometry plot showing the expression levels of AXL in the indicated MDA231 cells.\
(K) Box plot showing the superficial metastasis quantification after intravenous injection of MDA231 cells expressing the control-GFP or LTR-AXL constructs (n = 8/group).\
Error bars represent SEM. ^∗^p \< 0.05, ^∗∗∗∗^p \< 0.0001.](gr7){#fig7}
